Browse by author
Lookup NU author(s): Dr Jonathan Batty
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
To explore the pharmacogenetic effects of the cytochrome P450 (CYP)2D6 genotype in patients with systolic heart failure treated using controlled/extended-release (CR/XL) metoprolol, this study assessed the CYP2D6 locus for the nonfunctional *4 allele (1846G>A; rs3892097) in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF; n = 605). Participants were characterized as extensive, intermediate, or poor metabolizers (EMs, IMs, or PMs, respectively), based on the presence of the CYP2D6*4 allele (EM: *1*1, 60.4%; IM: *1*4, 35.8%; and PM: *4*4, 3.8%). Plasma metoprolol concentrations were 2.1-/4.6-fold greater in the IM/PM groups as compared with the EM group (P < 0.0001). Metoprolol induced significantly lower heart rates and diastolic blood pressures during early titration, indicating a CYP2D6*4 allele dose-response effect (P < 0.05). These effects were not observed at maximal dose, suggesting a saturable effect. Genotype did not adversely affect surrogate treatment efficacy. CYP2D6 genotype modulates metoprolol pharmacokinetics/pharmacodynamics during early titration; however, the MERIT-HF-defined titration schedule remains recommended for all patients, regardless of genotype.
Author(s): Batty JA, Hall AS, White HL, Wikstrand J, de Boer RA, van Veldhuisen DJ, van der Harst P, Waagstein F, Hjalmarson Å, Kjekshus J, Balmforth AJ
Publication type: Article
Publication status: Published
Journal: Clinical Pharmacology & Therapeutics
Year: 2014
Volume: 95
Issue: 3
Pages: 321-330
Print publication date: 01/03/2014
Online publication date: 06/11/2013
Acceptance date: 16/09/2013
ISSN (print): 0009-9236
ISSN (electronic): 1532-6535
Publisher: Nature Publishing Group
URL: http://dx.doi.org/10.1038/clpt.2013.193
DOI: 10.1038/clpt.2013.193
PubMed id: 24193112
Altmetrics provided by Altmetric
